Matchpoint Therapeutics raised $150 million in Series B financing to advance MPT-062 and its broader drug development pipeline.
- Amount
- $150M
- Stage
- Series B
- Announced
- 7 October 2026
- Leads
- Nextech Invest, Norwest
- Other investors
- Invus, BB Biotech, T1D Fund, BOLD Longevity Growth, Access Biotechnology, Atlas Venture, Sanofi Ventures, Digitalis Ventures
- Use of funds
- Advance lead asset MPT-062 to clinical proof-of-concept and broader product pipeline.
- Checked
- Announced by the company